Ocugen (OCGN) Research & Development (2014 - 2026)
Ocugen (OCGN) posted Research & Development of $11.3 million for Q1 2026, up 5.49% on a QoQ basis from $10.7 million in Q4 2025, and up 18.11% year-over-year from $9.5 million in Q1 2025.
Ocugen (OCGN) Research & Development (2014 - 2026) Analysis & Trends
Ocugen's Research & Development history runs 13 years deep, the most recent figure standing at $11.3 million for Q1 2026.
- Quarterly Research & Development rose 18.11% year-over-year to $11.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $41.5 million (up 19.08% YoY) and the FY2025 annual result came in at $39.8 million, up 23.73% from the prior year.
- Research & Development was $11.3 million for Q1 2026 at Ocugen, up from $10.7 million in the prior quarter.
- Across five years, Research & Development topped out at $17.9 million in Q3 2022 and bottomed at $6.8 million in Q1 2024.
- A 5-year average of $10.5 million and a median of $9.5 million in 2025 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development soared 227.05% — and 2023, when it sank 60.71%.
- Ocugen's Research & Development stood at $17.2 million in 2022, then plunged by 54.84% to $7.8 million in 2023, then rose by 6.57% to $8.3 million in 2024, then grew by 28.7% to $10.7 million in 2025, then advanced by 5.49% to $11.3 million in 2026.
- Business Quant data shows OCGN's Research & Development at $11.3 million in Q1 2026, $10.7 million in Q4 2025, and $11.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 1.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 541.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | -443.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 343.97 Mn |
| 10 | Ocugen | 399.60 Mn | 399.60 Mn | - | 11.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.26 Mn |
| Dec 31, 2025 | 10.67 Mn |
| Sep 30, 2025 | 11.15 Mn |
| Jun 30, 2025 | 8.40 Mn |
| Mar 31, 2025 | 9.53 Mn |
| Dec 31, 2024 | 8.29 Mn |
| Sep 30, 2024 | 8.11 Mn |
| Jun 30, 2024 | 8.90 Mn |
| Mar 31, 2024 | 6.83 Mn |
| Dec 31, 2023 | 7.78 Mn |
| Sep 30, 2023 | 7.05 Mn |
| Jun 30, 2023 | 14.57 Mn |
| Mar 31, 2023 | 10.17 Mn |
| Dec 31, 2022 | 17.23 Mn |
| Sep 30, 2022 | 17.94 Mn |
| Jun 30, 2022 | 11.60 Mn |
| Mar 31, 2022 | 9.39 Mn |
| Dec 31, 2021 | 7.10 Mn |
| Sep 30, 2021 | 6.28 Mn |
| Jun 30, 2021 | 18.85 Mn |